| [1] |
Ogurtsova K, da Rocha Fernandes JD, Huang Y，et al.IDF diabetes atlas：global estimates for the prevalence of diabetes for 2015 and 2040[J]． Diabetes Res Clin Pract， 2017(128):40-50.DOI： 10.1016/j.diabres.2017.03.024.
|
| [2] |
牛玲，李博一，张建伟，等．昆明地区糖尿病患者甲状腺结节患病率[J]．昆明医科大学学报，2017，38(5):78-82.
|
| [3] |
Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F，et al.The incidence and prevalence of thyroid dysfunction in europe：a meta-analysis[J]． J Clin Endocrinol Metab， 2014， 99(3):923-931.DOI： 10.1210/jc.2013-2409.
|
| [4] |
Centeno Maxzud M, Gómez Rasjido L, Fregenal M，et al.Prevalence of thyroid dysfunction in patients with type 2 diabetes mellitus[J]．Medicina(B Aires)，2016，76(6):355-358.
|
| [5] |
Subekti I, Pramono LA, Dewiasty E，et al.Thyroid dysfunction in type 2 diabetes mellitus patients[J]．Acta Med Indones，2017，49(4):314-323.
|
| [6] |
Wang H, Zhang H, Cao F，et al.Protection of insulin-like growth factor 1 on experimental peripheral neuropathy in diabetic mice[J]． Mol Med Rep， 2018， 18(5):4577-4586.DOI： 10.3892/mmr.2018.9435.
|
| [7] |
Mancuso E, Mannino GC, Fatta CD，et al.Insulin-like growth factor-1 is a negative modulator of glucagon secretion[J]． Oncotarget， 2017， 8(31):51719-51732.DOI： 10.18632/oncotarget.18514.
|
| [8] |
Maximus PS.Insulin like growth factor 1 is linked to higher cardiovascular risk score in adults with type 2 diabetes mellitus and chronic kidney disease[J]． Diabetes Metab Syndr， 2019， 13(4):2613-2618.DOI： 10.1016/j.dsx.2019.07.008.
|
| [9] |
Aguirre GA, González-Guerra JL, Espinosa L，et al.Insulin-like growth factor 1 in the cardiovascular system[J]． Rev Physiol Biochem Pharmacol， 2018(175):1-45.DOI： 10.1007/112_2017_8.
|
| [10] |
Nederstigt C, Corssmit EP, de Koning EJ，et al.Incidence and prevalence of thyroid dysfunction in type 1 diabetes[J]． J Diabetes Complications， 2016， 30(3):420-425.DOI： 10.1016/j.jdiacomp.2015.12.027.
|
| [11] |
Gu Y, Li H, Bao X，et al.The relationship between thyroid function and the prevalence of type 2 diabetes mellitus in euthyroid subjects[J]． J Clin Endocrinol Metab， 2017， 102(2):434-442.DOI： 10.1210/jc.2016-2965.
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
胡晓黎.2型糖尿病合并甲状腺功能异常的临床分析[J]．特别健康，2019(36):64.
|
| [17] |
Subekti I, Pramono LA, Dewiasty E，et al.Thyroid dysfunction in type 2 diabetes mellitus patients[J]．Acta Med Indones，2017，49(4):314-323.
|
| [18] |
Sierra-Johnson J, Romero-Corral A, Somers VK, et al. IGF-I/IGFBP-3 ratio：a mechanistic insight into the metabolic [J]． Clin Sci(Lond)， 2009， 116(6):507-512.DOI： 10.1042/CS20080382.
|
| [19] |
Åsvold BO, Vatten LJ, Midthjell K, et al. Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism：11-year follow-up of the HUNT Study in Norway[J]． J Clin Endocrinol Metab， 2012， 97(1):93-99.DOI： 10.1210/jc.2011-1724.
|
| [20] |
Kadiyala R, Peter R, Okosieme OE.Thyroid dysfunction in patients with diabetes：clinical implications and screening strategies[J]． Int J Clin Pract， 2010， 64(8):1130-1139.DOI： 10.1111/j.1742-1241.2010.02376.x.
|
| [21] |
Shapiro MR, Wasserfall CH, McGrail SM，et al.Insulin-like growth factor dysregulation both preceding and following type 1 diabetes diagnosis[J]． Diabetes， 2020， 69(3):413-423.DOI： 10.2337/db19-0942.
|
| [22] |
Drogan D, Schulze MB, Boeing H，et al.Insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in relation to the risk of type 2 diabetes mellitus：results from the EPIC-potsdam study[J]． Am J Epidemiol， 2016， 183(6):553-560.DOI： 10.1093/aje/kwv188.
|
| [23] |
孙娜娜，韩立坤．男性2型糖尿病合并良性甲状腺结节患者的内分泌激素特征[J]．中国医科大学学报，2019，48(6):515-518,524.
|
| [24] |
Yamanaka Y, Wilson EM, Rosenfeld RG，et al.Inhibition of insulin receptor activation by insulin-like growth factor binding proteins[J]． J Biol Chem， 1997， 272(49):30729-30734.DOI： 10.1074/jbc.272.49.30729.
|
| [25] |
|
| [26] |
Martin S, Sirbu A, Betivoiu M, et al. IGF1 deficiency in newly diagnosed Graves′ disease patients[J]． Hormones (Athens)， 2015， 14(4):651-659.DOI： 10.14310/horm.2002.1577.
|
| [27] |
Morgan SJ, Neumann S, Marcus-Samuels B，et al.Thyrotropin and insulin-like growth factor 1 receptor crosstalk Upregulates sodium-iodide Symporter expression in primary cultures of human Thyrocytes[J]． Thyroid， 2016， 26(12):1794-1803.DOI： 10.1089/thy.2016.0323.
|
| [28] |
Krieger CC, Boutin A, Jang D, et al. Arrestin-beta-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk[J]． Endocrinology， 2019， 160(6):1468-1479.DOI： 10.1210/en.2019-00055.
|
| [29] |
Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease[J]． N Engl J Med， 2020， 382(4):341-352.DOI： 10.1056/NEJMoa1910434.
|
| [30] |
|
| [31] |
Altas A, Kuzu F, Arpaci D，et al.The clinical values of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels in blood and thyroid nodules[J]． Int J Endocrinol， 2017(2017):3145234.DOI： 10.1155/2017/3145234.
|
| [32] |
Schmidt JA, Allen NE, Almquist M, et al. Insulin-like growth factor-1 and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition[J]． Cancer Epidemiol Biomarkers Prev， 2014， 23(6):976-985.DOI： 10.1158/1055-9965.EPI-13-1210-T.
|
| [33] |
Lawnicka H, Motylewska E, Borkowska M，et al.Elevated serum concentrations of IGF-1 and IGF-1R in patients with thyroid cancers[J]． Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub， 2020， 164(1):77-83.DOI： 10.5507/bp.2019.018.
|
| [34] |
|
| [35] |
|
| [36] |
Kimura T, Van Keymeulen A, Golstein J，et al.Regulation of thyroid cell proliferation by TSH and other factors：a critical evaluation of in vitro models[J]． Endocr Rev， 2001， 22(5):631-656.DOI： 10.1210/edrv.22.5.0444.
|
| [37] |
|
| [38] |
|